Výsledky vyhledávání - "Angeles Fernández-Rodríguez"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Universidad de Almería
EUROPEAN JOURNAL OF HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO. Repositorio Institucional de Producción Científica

[Background]: Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old popu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db91a8b053c596692384d95d1bbdd342
http://hdl.handle.net/10261/220424

Zobrazit plný text záznamu

Akademický článek

Plasma-Based Scaffold Containing Bone-Marrow Mononuclear Cells Promotes Wound Healing in a Mouse Model of Pressure Injury

Autor: Maria Alvarez-Viejo, Luis Romero-Rosal, Marcos Perez-Basterrechea, Jose M. García-Gala, Pablo Hernando-Rodriguez, Jesus Marana-Gonzalez, Miriam Rubiera-Valdes, Blanca Vivanco-Allende, Angeles Fernandez-Rodriguez, Eva Martinez-Revuelta, Silvia Perez-Lopez

Publikováno v: Cell Transplantation, Vol 33 (2024)

Pressure injuries, or pressure ulcers, are a common problem that may lead to infections and major complications, besides being a social and economic burden due to the costs of treatment and hospitalization. While surgery is sometimes necessary, this

Externí odkaz: https://doaj.org/article/8130a620d30542a592763fc4a4b73f64

Zobrazit plný text záznamu

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

Autor: María Perera, Montserrat Cortés, Erika Coria, Miguel Angel Fuertes-Palacio, Laura Solán, Isabel Caparrós, Inés Valcarce, Isidro Jarque, Carlos Aguilar, R. Jiménez, Pilar Galan, Silvia Bernat, Tomás José González-López, Pável E Olivera, Mónica Martín-Salces, Adriana Sainz, María Carmen Arratibel, María Paz Martínez-Badas, Maria Eva Mingot-Castellano, Manuel González-Silva, Fernando Fernández-Fuertes, Rafael Feito Alonso, Erik de Cabo, Juan Andrés Vázquez-Paganini, Angeles Fernández-Rodríguez, Susana Pérez-Crespo, Paola Beneit, Carmen Fernández-Miñano, Rosa Fisac, Carmen de Cos, Maria José Cortti, Violeta Martínez-Robles, Jose Angel Hernandez-Rivas, Alberto Casaus, Armando Luaña, Isabel Gutierrez-Jomarrón, Arancha Alonso, Cristina Fernández-Canal, María Teresa Álvarez-Román, María Jesús Peñarrubia, Javier García-Frade, Marcio M Andrade, José Ramón González-Porras, Marta Gómez-Nuñez, María Calbacho, Gloria Pérez-Rus, Cristina Pascual, Blanca Sanchez-Gonzalez

Publikováno v: American Journal of Hematology. 90:E40-E43

Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51bdd0e8fe6218ff5b4f6f1ed793dbab
https://doi.org/10.1002/ajh.23900

Zobrazit plný text záznamu

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

Autor: Esther Arrieta-Cerdán, Angeles Fernández-Rodríguez, Abelardo Bárez, Silvia Bernat, José Ramón González-Porras, María Teresa Álvarez-Román, Luis Javier García-Frade, Gloria Pérez-Rus, Tomás José González-López, Jose Angel Hernandez-Rivas, Fernando Fernández-Fuertes, María Jesús Peñarrubia, Blanca Sanchez-Gonzalez, Cristina Pascual, Pável E Olivera, Violeta Martínez-Robles, Carlos Aguilar, Erik de Cabo

Publikováno v: International journal of hematology. 106(4)

Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report Spanish results for this type of patients. We retr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b844cf400f8b90d68311f46d0136cca
https://pubmed.ncbi.nlm.nih.gov/28667351

Zobrazit plný text záznamu

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

Publikováno v: EUROPEAN JOURNAL OF HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

BackgroundEltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772c8d3ec436e2c6ea29690e89935796
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2007

Zobrazit plný text záznamu

Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice

Publikováno v: Blood. 126:2263-2263

Background: Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) drug approved in primary chronic ITP. Lack of clinical trials in secondary ITP avoids a clear demonstration of its potential in terms of safety and efficacy on secondary ITP.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::796d02854f7d2c064047d18a346ed1e6
https://doi.org/10.1182/blood.v126.23.2263.2263

Zobrazit plný text záznamu

Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP

Publikováno v: Blood. 126:4657-4657

Background: Eltrombopag is a thrombopoietin receptor agonist approved for primary chronic ITP patients. Due to the non-existence of clinical trials using eltrombopag in persistent and newly diagnosed ITP, there are no clear data about its usefulness

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dcb3d017b5e4b4b577fcf73f41cf4d33
https://doi.org/10.1182/blood.v126.23.4657.4657

Zobrazit plný text záznamu

Use of Eltrombopag after Romiplostim in Primary ITP Patients

Autor: Manuel González-Silva, Angeles Fernández-Rodríguez, Susana Pérez-Crespo, Erika Coria, Silvia Bernat, Violeta Martínez-Robles, Marta Gómez-Nuñez, María Eva Mingot, Pilar Galan, Rosa Fisac, María Perera, Cristina Fernández-Canal, Gloria Pérez-Rus, Rafael Feito Alonso, Miguel Angel Fuertes-Palacio, Carmen de Cos, Cristina Pascual, María Calbacho, Carmen Fernández-Miñano, María Carmen Arratibel, Carlos Aguilar, Laura Solán, Isabel Caparrós, Fernando Fernández-Fuentes, Tomás José González-López, María Paz Martínez-Badas, José Ramón González-Porras, Juan Andrés Vázquez-Paganini, Montserrat Cortés, Maria José Cortti, Francisco Javier Díaz-Gálvez, Paola Beneit, Isidro Jarque, Luis Miguel Juárez-Salcedo, Jose Angel Hernandez-Rivas, Alberto Casaus, Adriana Sainz, R. Jiménez, Javier García-Frade, Marcio M Andrade, Armando Luaña, María Teresa Álvarez-Román, Inés Valcarce, Blanca Sanchez-Gonzalez, Pável E Olivera, Arancha Alonso, Mónica Martín-Salces, María Jesús Peñarrubia

Publikováno v: Blood. 124:2790-2790

Background: The trombopoietin receptor agonists (TRAs) romiplostim and eltrombopag are effective and safe in the treatment of chronic immune thrombocytopenia (ITP). However, when no response is achieved or when adverse events occur with one TRA the v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::91dab2ddcc894fc8c8e5e1009b100756
https://doi.org/10.1182/blood.v124.21.2790.2790

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání